Loading
AT
Acorda Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Mar 2023.
Acorda Therapeutics Inc: what insiders have been doing
Every trade that managers of Acorda Therapeutics Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Ardsley, United States. It was founded in 1995. Nothing new has been filed by managers of Acorda Therapeutics Inc in twelve months, the latest record being from 20 March 2023.
Since 2016, the database holds 1 purchase and 3 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
15
Thresholds
n/a
Buy Volume
€5,758
1 ops. · all time
Sell Volume
€3,533
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$101.3M
Net income-US$217.7M-215.0% margin
Last declaration on 20 March 2023
Declarations15 total
1,511 shares@ US$0.398100.0% of flowCommon StockSEC:0001209191-22-048947:0
1,511 shares@ US$0.3989.8% of flowCommon StockSEC:0001209191-22-048948:0
448 shares@ US$4.38100.0% of flowCommon StockSEC:0001209191-21-055100:0
1,511 shares@ US$4.3890.2% of flowCommon StockSEC:0001209191-21-055101:0
542 sharesCommon StockSEC:0001209191-16-089496:0
2,689 sharesCommon StockSEC:0001209191-16-089496:1
10,000 sharesCommon StockSEC:0001209191-16-089496:2
13,131 sharesCommon StockSEC:0001209191-16-089496:3
100 sharesCommon StockSEC:0001209191-16-089496:4
15 of 15 declarations
About Acorda Therapeutics Inc
Acorda Therapeutics Inc. is a U.S.-based biopharmaceutical company that historically focused on neurological disorders and functional recovery. The company was listed on the NASDAQ market in the United States, and its operations were built around specialty drugs aimed at improving mobility and quality of life for patients with chronic nervous-system conditions. Acorda was founded in the early 1990s and was long headquartered in Pearl River, New York. Its corporate profile changed dramatically in 2024, when the company entered Chapter 11 bankruptcy protection and subsequently transferred substantially all of its operating assets.
From an industry perspective, Acorda became known for developing and commercializing therapies in multiple sclerosis and Parkinson’s disease. Its best-known products were AMPYRA (dalfampridine), indicated in the U.S. to improve walking in certain patients with multiple sclerosis, and INBRIJA (levodopa inhalation powder), used for intermittent treatment of OFF episodes in patients with Parkinson’s disease treated with carbidopa/levodopa. The company also owned ARCUS, an inhalation-delivery technology platform that added strategic value beyond the marketed brands themselves. In addition, Acorda had international exposure through FAMPYRA, the ex-U.S. branded version of fampridine used in multiple sclerosis-related walking impairment.
Read moreShow less
Before the restructuring, Acorda occupied a niche position in specialty neurology. It was not a broad diversified pharmaceutical player, but rather a focused commercial-stage biotech with a concentrated portfolio and a relatively small number of key assets. That made the business highly dependent on product performance, patent and lifecycle management, payer access, and regulatory execution. For investors, this meant the equity case was driven by asset-specific economics rather than scale.
Recent developments are central to any current assessment. In 2024, Acorda entered Chapter 11 in the United States and agreed to sell substantially all of its assets to Merz Therapeutics, including INBRIJA, AMPYRA, and FAMPYRA. Company disclosures stated that Acorda exited Chapter 11 on August 21, 2024, and that remaining assets were transferred to the Acorda Therapeutics Liquidation Trust. In practical terms, Acorda’s former operating business was wound down, while the entity continued to appear in SEC filings, including insider Form 4 transactions. For international investors analyzing U.S. listed healthcare names, Acorda should now be viewed primarily as a restructuring/liquidation case rather than a going-concern growth pharmaceutical company.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
